Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in T2D with NAFLD
NCT06218342Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of henagliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by Sir Run-Run Shaw Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06218342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218342.